IPO Boutique

Avalanche Biotechnologies, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Avalanche Biotechnologies, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Avalanche Biotechnologies, Inc.AAVL -
NASDAQ
$13.00-$15.00 $17.00 $25.005.4 million7/31/2014
Jefferies, Cowen & Co., Piper Jaffray
Co-Manager(s):
William Blair
Health Care
Filing(s):

Filed 2014-06-30
Terms Added 2014-07-21



Avalanche Biotechnologies, Inc. Quote & Chart - Click for current quote - AAVL

About Avalanche Biotechnologies, Inc. (adapted from Avalanche Biotechnologies, Inc. prospectus):
They are a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

This description is adapted from Avalanche AAVL prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as Avalanche AAVL "AAVL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved